Dr. Chan specializes in the surgical and medical treatment of ovarian and other
pelvic cancers at CPMC. He is board certified in gynecologic oncology, and obstetrics
and gynecology. He is investigating new treatments for gynecologic cancers,
including targeted biologic therapies, and exploring the role of tumor-initiating
cells in ovarian cancer. A clinician and surgeon, Dr. Chan is a principal investigator
of studies assessing the treatment and health outcomes of ovarian and uterine cancer
patients.
Sutter Health Research Enterprise
1501 Trousdale Drive
Burlingame, CA, 94010
(415) 751-1847
ChanJK@Sutterhealth.org
Primary Research Interests
Related Clinical Trials
Locally Advanced or Metastatic (Roche YO40482)
Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab
to Patients With Advanced Platinum-sensitive Ovarian Cancer
Investigators: John Chung-Kai Chan M.D., Lejla Delic MD
Metastatic (NRG GY018) Temp Amendment Hold
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy
Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
Investigator: John Chung-Kai Chan M.D.
Status: Active, Not Recruiting
Metastatic or Locally Advanced (Agenus GOG 3028) Temp Enrollment Hold
Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line
Cervical Cancer
Investigators: John Chung-Kai Chan M.D., Lejla Delic MD
Status: Active, Not Recruiting
QOL (GOG 0278)
Studying the Physical Function and Quality of Life Before and After Surgery in Patients
With Stage I Cervical Cancer
Investigator: John Chung-Kai Chan M.D.
Status: Active, Recruiting